UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, that develops medicines and solutions for people living with severe diseases in the fields of neurology and immunology. Established in 1928 as Union Chimique Belge, the company has grown to become a recognized leader in the discovery, development and commercialization of therapies that address unmet medical needs. UCB’s operations span across Europe, North America, Latin America and the Asia-Pacific region, serving millions of patients through its prescription medicines and patient support programs.
The company’s portfolio includes established treatments such as Cimzia (certolizumab pegol) for autoimmune disorders, Vimpat (lacosamide) and Keppra (levetiracetam) for epilepsy, and Neupro (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome. UCB also offers Evenity (romosozumab-aqqg) for osteoporosis and recently introduced Bimzelx (bimekizumab) for plaque psoriasis, reflecting its commitment to expanding into adjacent therapeutic areas. Its robust pipeline comprises clinical-stage candidates targeting conditions such as gout, rare diseases and debilitating chronic inflammatory disorders.
Since its founding, UCB has invested heavily in research and development, operating multiple research hubs in Belgium and strategic innovation centers in the United States and Asia. The company collaborates with academic institutions, biotech partners and patient organizations to accelerate the translation of scientific discoveries into novel treatments. UCB’s integrated model brings together in-house expertise in medicinal chemistry, protein engineering and clinical innovation, supported by a global manufacturing network that ensures consistent supply and quality of its therapies.
UCB trades under the symbol UCBJY on the OTC Markets and is governed by a diverse executive leadership team. Under the direction of CEO Jean-Christophe Tellier, the company continues to refine its focus on specialty care, digital health solutions and patient-centric initiatives. With a strategic emphasis on sustainable growth and scientific excellence, UCB aims to enhance the lives of people living with severe diseases while building long-term value for shareholders and stakeholders alike.
AI Generated. May Contain Errors.
